Nomogram for the Prediction of Contrast-associated Acute Kidney Injury in Patients with Hypoalbuminemia Undergoing Coronary Angiography

Liwei Liu  
The Second School of Clinical Medicine, Southern Medical University  
https://orcid.org/0000-0001-7209-9212

Jin Liu  
Guangdong Cardiovascular Institute

Li Lei  
Guangdong Cardiovascular Institute

Bo Wang  
Guangdong Cardiovascular Institute

Guoli Sun  
Guangdong Cardiovascular Institute

Zhaodong Guo  
Guangdong Cardiovascular Institute

Yibo He  
Guangdong Cardiovascular Institute

Feier Song  
Guangdong Provincial People's Hospital

Zhubin Lun  
Dongguan People's Hospital

Bowen Liu  
South China University of Technology

Guanzhong Chen  
South China University of Technology

Shiqun Chen  
Guangdong Cardiovascular Institute

Yongquan Yang  
Guangdong Cardiovascular Institute

Jiyan Chen  
Guangdong Cardiovascular Institute

Yong Liu (liuyong2009@126.com)
Keywords: Contrast-associated kidney injury, Hypoalbuminemia, Nomogram, Coronary angiography, Percutaneous coronary intervention

DOI: https://doi.org/10.21203/rs.3.rs-34291/v1

License: ☕️ 📧 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Risk stratification is recommended as the key step to prevent contrast-associated acute kidney injury (CA-AKI) by allowing for prevention among at-risk patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI). Patients with hypoalbuminemia are prone to CA-AKI and do not have their own risk stratification tool. Therefore, we developed and validated a nomogram for predicting CA-AKI in patients with hypoalbuminemia undergoing CAG/PCI.

**Methods:** A total of 1272 consecutive patients with hypoalbuminemia undergoing CAG/PCI were enrolled and randomly assigned (2:1 ratio) to a development cohort (n = 848) and a validation cohort (n = 424). CA-AKI was defined as a serum creatinine (SCr) increase of $\geq 0.3$ mg/dL or 50% from baseline within the first 48 to 72 hours following CAG/PCI. A nomogram was established with independent predictors according to multivariate logistic regression and a stepwise approach. The discrimination of the nomogram was assessed by the area under the receiver operating characteristic (ROC) curve and was compared to the classic Mehran CA-AKI score. Calibration was assessed using the Hosmer–Lemeshow test.

**Results:** Overall, 8.4% (71/848) of patients in the development cohort and 11.2% (48/424) of patients in the validation cohort experienced CA-AKI. The simple nomogram included estimated glomerular filtration rate (eGFR), serum albumin (ALB), age and the use of intra-aortic balloon pump (IABP); showed better predictive ability than the Mehran score (C-index 0.756 vs. 0.693, $p = 0.02$); and had good calibration (Hosmer–Lemeshow test $p = 0.187$). Decision curve analysis showed that the nomogram was more clinically useful than the Mehran score.

**Conclusions:** Our data suggested that the simple nomogram might be a good tool for predicting CA-AKI in high-risk patients with hypoalbuminemia undergoing CAG/PCI, but our findings require further external validation.

**Trial registration number** NCT01400295

Background

Contrast-associated acute kidney injury (CA-AKI) is one of the major complications that occurs after contrast exposure [1] and is significantly associated with higher mortality and worsened clinical outcomes [2]. Guidelines recommend that patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) should be assessed for the risk of CA-AKI [3].

Hypoalbuminemia is a frequent problem in patients with cardiovascular disease, with a prevalence ranging from 10–40% in coronary artery disease patients [4–7]. Previous studies have shown that hypoalbuminemia is an independent risk factor for CA-AKI [8] after adjusting for chronic kidney disease(CKD), age or congestive heart failure(CHF). Moreover, the development of AKI is associated with worse survival than the absence of AKI in patients with baseline hypoalbuminemia [9].
Although patients complicated with hypoalbuminemia are at high risk of CA-AKI, based on a systematic search, there is no prediction model to identify such patients. A recent review concluded that only a few published models are available for routine clinical use [10]. Therefore, we conducted this study to establish a simple nomogram for the assessment of CA-AKI risk among patients with hypoalbuminemia undergoing CAG/PCI.

**Methods**

**Patients**

This prospective cohort study reviewed all consecutive patients aged $\geq 18$ years with baseline hypoalbuminemia [hypoalbuminemia was defined as serum albumin less than 3.5 g/L ($< 35$ mg/dl)] who were undergoing CAG or PCI and who were included in a prospective observation cohort (PREdictive Value of COntrast voluMe to creatinine Clearance Ratio, PRECOMIN, NCT01400295) in Guangdong Provincial People's Hospital between January 2010 and October 2012 [11]. The exclusion criteria included pregnancy, lactation, intravascular administration of contrast medium within the previous 7 days or 3 days post operation, no use of low-osmolarity contrast agents, cardiovascular surgery or endovascular repair, end-stage renal disease or renal replacement, missing preoperative or postoperative creatinine data, malignancy, and no use of isotonic saline for hydration. The Ethics Committee of the Guangdong Provincial People's Hospital approved this study. All the patients involved provided written informed consent.

Finally, approximately 1272 patients were included in the analysis. All eligible patients were randomly (2:1) assigned to a development cohort (n = 848) and a validation cohort (n = 424). The mean follow-up time was 7.7 (6.8; 8.8) years. All follow-up events were carefully monitored and recorded by trained nurses through office visits or telephone interviews.

**Endpoint and definitions**

The endpoint of this study was CA-AKI defined as a Scr elevation of $\geq 0.3$ mg/dL or 50% from baseline within the first 48 to 72 hours following contrast exposure [12]. CKD was defined as an estimated glomerular filtration rate (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) formula $< 60$ mL/min/1.73 m$^2$. The definitions of intra-aortic balloon pump (IABP), hypotension, diabetes, and CHF were the same as those used in the Mehran score [13]. Serum albumin (ALB) was analyzed by an automatic biochemical analyzer (Beckman Coulter AU5800, Ireland). The left ventricular ejection fraction (LVEF) was evaluated in all patients using echocardiography within 24 hours before the procedure. Follow-up of mortality was carefully monitored and recorded by trained nurses through office visits and telephone interviews at 1 and 6 months and every 1 year after enrollment until April 2019.

**Statistical analysis**

Normally distributed continuous variables were compared with an unpaired, 2-tailed t test and are expressed as the mean $\pm$ SD, while nonnormally distributed variables were compared through the
Wilcoxon rank-sum test and are expressed as the median ± interquartile. Categorical variables were analyzed using the $\chi^2$ test or Fisher’s exact test and expressed as percentages. Kaplan-Meier curves were used to explore the association between the CA-AKI and long-term mortality. Multivariate Cox proportional hazards regression was used to evaluate the impact of CA-AKI on the long-term mortality [14, 15].

The associations between CA-AKI and variables in the development cohort were assessed by univariable logistic analysis. Variables with missing values > 15% were not considered candidates. Significant predictors from the univariable logistic analysis were then included in the multivariable logistic analysis to fit a prediction model. A backward stepwise approach was performed to create a reduced model by successively removing nonsignificant covariates (P > 0.1) until all the remaining predictors were statistically significant. For all logistic regression analyses, odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. Collinearity between variables was also evaluated. A nomogram was then formulated based on the results and by using the rms package of R. To form the nomogram, each regression coefficient in multivariate logistic regression was proportionally converted into a 0- to 100-point scale. The variable with the highest $\beta$ coefficient (absolute value) was assigned 100 points. The total points were calculated by adding points of each variable, which were finally converted to predicted probabilities. To assess the clinical use of the nomogram, the final nomogram was tested in the validation cohort. The performance of the nomogram was assessed using the area under the receiver operating characteristic (ROC) curve and concordance index (C index). The nomogram was internally validated with 1000 bootstrap samples to decrease the overfit bias [16, 17]. Calibration was assessed using the Hosmer–Lemeshow test and shown with a calibration curve. The area under the curve (AUC) was calculated in both the development and validation cohorts and compared to that of the Mehran score. Finally, decision curve analysis was performed to compare the clinical discriminative abilities between the new nomogram and the Mehran model.

Missing data were not imputed. In all analyses, $P < 0.05$ was considered statistically significant. All analyses were conducted with R software (version 3.6.2; R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 25.0).

Results

Baseline characteristics

During this study period, 1272 consecutive patients who had preprocedure hypoalbuminemia were enrolled and divided into the development cohort (n = 848) and the validation cohort (n = 424). In the total cohort, the incidence of CA-AKI was 9.36% (119/1272). The incidence of CA-AKI in the development cohort and validation cohort was 8.4% (71/848) and 11.2% (48/424), respectively. There were 286 (22.5%) female patients. The mean age was 66.00 ± 10.63 years, and the mean Scr was 102.09 ± 53.63 µmol/L. No significant difference was identified between the development and validation cohorts, except for in hydration volume (Table 1).
Table 1
Baseline characteristics of the development cohort and validation cohort

|                      | Development (n = 844) | Validation (n = 428) | p  |
|----------------------|----------------------|----------------------|----|
| Age, y               | 66.02 (10.44)        | 65.96 (11.02)        | 0.921 |
| Female, n (%)        | 204 (24.2)           | 82 (19.2)            | 0.051 |
| Weight, n            | 63.48 (10.10)        | 62.62 (10.49)        | 0.361 |
| SBP, mmHg            | 127.66 (20.48)       | 128.85 (20.78)       | 0.329 |
| DBP, mmHg            | 74.30 (12.08)        | 74.92 (12.31)        | 0.385 |
| HR, bpm              | 75.61 (13.73)        | 75.60 (14.41)        | 0.989 |
| **Medical history**  |                      |                      |    |
| CKD, n (%)           | 251 (29.7)           | 105 (24.5)           | 0.059 |
| AMI, n (%)           | 378 (45.1)           | 202 (47.3)           | 0.495 |
| Hypertension, n (%)  | 494 (58.5)           | 250 (58.5)           | 1    |
| Prehypotension, n (%)| 13 (1.5)             | 9 (2.1)              | 0.621 |
| Hyperlipidemia, n (%)| 99 (11.7)            | 40 (9.3)             | 0.233 |
| Anemia, n (%)        | 346 (41.6)           | 179 (42.2)           | 0.878 |
| DM, n (%)            | 219 (25.9)           | 96 (22.5)            | 0.2   |
| CHF, n (%)           | 198 (23.6)           | 87 (20.4)            | 0.227 |
| LVEF, n              | 56.28 (12.98)        | 55.39 (12.16)        | 0.262 |
| NYHA                 | 1.92 (0.76)          | 1.87 (0.67)          | 0.317 |
| **Laboratory examination** |                |                      |    |
| eGFR, mL/min/1.73 m² | 72.30 (22.57)        | 73.42 (21.68)        | 0.395 |
| Scr, µmol/L          | 103.03 (59.22)       | 100.22 (40.16)       | 0.379 |
| ALB, g/l             | 31.59 (2.72)         | 31.60 (2.74)         | 0.96  |

Abbreviations: CA-AKI: contrast-associated acute kidney injury; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CKD: chronic kidney disease; AMI: acute myocardial infarction; DM: diabetes mellitus; CHF: congestive heart failure; LVEF: left ventricular ejection fraction; NYHA: NYHA classification grading of cardiac function; eGFR: estimated glomerular filtration rate; ALB: serum albumin; Lpa: lipoprotein a; BUN: blood urea nitrogen; Dose: dose of contrast media; IABP: intra-aortic balloon pump; Scr: serum creatinine
## Development and validation of a CA-AKI-predicting nomogram

The results of univariate logistic analysis about associations with CA-AKI are shown in Table 2. Through multivariate logistic analysis and stepwise approach, age (OR: 1.036 95% CI: 1.006–1.007), IABP (OR:
8.267 95% CI: 4.007 – 16.978, eGFR (OR: 0.982 95% CI: 0.970–0.994) and ALB (OR: 0.875 95% CI: 0.801–0.955) were selected as predictors of CA-AKI (Table 3).

Table 2
Univariate logistic regression

|          | OR     | 95% CI             | P      |
|----------|--------|--------------------|--------|
| eGFR     | 0.968  | 0.957–0.979        | < 0.001|
| Scr      | 1.006  | 1.003–1.010        | < 0.001|
| Age      | 1.058  | 1.030–1.088        | < 0.001|
| AMI      | 2.113  | 1.290–3.520        | 0.003  |
| NYHA     | 2.290  | 1.587–3.308        | < 0.001|
| CKD      | 3.664  | 2.237–6.066        | < 0.001|
| Hypertension | 2.404 | 1.397–4.342      | 0.002  |
| IABP     | 12.788 | 6.558–24.868       | < 0.001|
| CHF      | 3.848  | 2.34–6.338         | < 0.001|
| LVEF     | 0.966  | 0.949–0.984        | < 0.001|
| HR       | 1.018  | 1.005–1.031        | 0.005  |
| Anemia   | 1.802  | 1.106–2.956        | < 0.001|
| BUN      | 1.131  | 1.067–1.197        | < 0.001|
| Diuretics| 1.658  | 1.084–2.465        | 0.015  |
| Beta-blocker | 0.51 | 0.302–0.885    | 0.014  |
| Hydration volume | 1.001 | 1.000-1.001 | < 0.001|

Abbreviations: CA-AKI: contrast-associated acute kidney injury; eGFR: estimated glomerular filtration rate; AMI: acute myocardial infarction; Dose: dose of contrast media; IABP: intra-aortic balloon pump; CHF: congestive heart failure; LVEF: left ventricular ejection fraction; HR: heart rate; ALB: serum albumin; BUN: blood urea nitrogen; infarction; Scr: serum creatinine
Table 3
Multivariate logistic regression

| OR     | 95% CI        | p       |
|--------|---------------|---------|
| eGFR   | 0.982         | 0.97–0.994 | 0.004   |
| ALB    | 0.875         | 0.801–0.955 | 0.002   |
| IABP   | 8.267         | 4.007–16.978 | <0.001 |
| Age    | 1.036         | 1.006–1.067 | 0.018   |

Abbreviations: eGFR: estimated glomerular filtration rate; ALB: serum albumin; IABP: intra-aortic balloon pump;

These independently associated risk factors were used to form a simple nomogram for CA-AKI (Fig. 1). In the development cohort, the nomogram demonstrated good discriminative power in estimating the risk of CI-AKI, with an unadjusted C-statistic of 0.816 (95% CI, 0.763–0.862) and a bootstrap-corrected C statistic of 0.802. Compared to the Mehran score, the nomogram had good discrimination (AUC 0.816 VS 0.775, p = 0.082, Fig. 2). In addition, calibration plots graphically showed good agreement regarding the presence of CA-AKI between the risk estimation and the observed frequency (Fig. 3). The Hosmer–Lemeshow statistic of multivariable analysis suggested a good fit ($\chi^2 = 3.65, P = 0.887$) in the development cohort.

In the validation cohort, the simple nomogram demonstrated a C-statistic of 0.756 (95% CI 0.685–0.832), which was better than that of the Mehran score (AUC: 0.693, 95% CI 0.608–0.779) among patients (P = 0.02, Fig. 4). This means that there is no significant difference between the model’s predicted value and the actual predicted value. Moreover, there was also a good calibration curve for risk estimation (Fig. 3). The Hosmer–Lemeshow statistic of multivariable analysis did not perform a lack of fit ($\chi^2 = 11.27, P = 0.187$) in the validation cohort. Decision curve analysis was used to facilitate the comparison between the new nomogram and the Mehran score. The clinical usefulness of new nomogram was better than that of the Mehran score in development and validation cohort (Supplementary Fig. 1A and B).

Follow-up of clinical outcomes

We divided patients into 2 groups according to whether they developed CA-AKI. The median follow-up period was 7.7 (6.8; 8.8) years. The rates of mortality were 30.2% and 17.1% in the CA-AKI group and non-CA-AKI group, respectively. According to the log-rank analysis (Fig. 5), patients with CA-AKI presented a worse long-term outcome (P < 0.01). By multivariate Cox regression analysis, CA-AKI was independently associated with the long-term mortality (Hazard ratio:1.53, 95% CI 1.03–2.25) after adjusting for diabetes, age, gender, CHF, AMI, hypertension, IABP and eGFR (Supplementary Table 2).

Discussion
Our study was the first to develop a CA-AKI risk stratification model in a population with hypoalbuminemia. We established a simple nomogram that included four powerful predictors for clinical use (IABP, ALB, eGFR, age). Compared to the classical Mehran score, the new simple nomogram had good discrimination and calibration in predicting CA-AKI.

In our study, the incidence of CA-AKI was 9.36%, which was relatively high but similar to the high-risk population, such as patients with CKD or AMI [18, 19]. Several studies have demonstrated that hypoalbuminemia is an independent risk factor for CA-AKI [8] and is closely related to poor prognosis in coronary heart disease [20]. Yu et al. [9] reported that patients with hypoalbuminemia had a high incidence of AKI in the hospital. Furthermore, in our study, the development of CA-AKI was associated with a poor prognosis according to the results of the 7-year follow-up, which suggested the importance of CA-AKI prevention.

Risk assessment in high-risk groups is a primary aim and important for the prevention of CA-AKI, so a large number of models have been proposed [10]. Although the classic Mehran score or other models had good predictive efficiency, most models included 5–8 variables, and some factors required the subjective judgment of clinicians. In recent years, predictive models have been established for different populations at high risk of CA-AKI, such as patients with CKD [21], AMI [22] or diabetes mellitus [23]. However, there was no predictive model for patients with hypoalbuminemia. Because of the high incidence of CA-AKI in patients with hypoalbuminemia, it is important to develop a simple risk score for these patients undergoing CAG/PCI.

For predicting CA-AKI, the currently available models seldom included albumin [10] because serum albumin was a novel laboratory risk factor. Murat et al. [8] suggested that albumin is an independent and good predictor of CA-AKI among patients with ACS undergoing PCI. Low serum albumin concentrations reflect the inflammatory state of the body, which may lead to CA-AKI [24].

The use of IABP was the strongest predictor of CA-AKI in the present model. IABP, a reflection of hemodynamics, was an independent predictor of CI-AKI, which has been reported in previous studies [21, 25]. Bartholomew et al. [26] first reported a close association between the use of IABP and CA-AKI, and then Mehran et al. [13] first included IABP in a model of CA-AKI prediction. Perioperative hemodynamic disorders may lead to ischemia-reperfusion injury, which may have a potential contribution to AKI.

In the present risk model, age was an independent predictor of the occurrence of CI-AKI [13, 27]. This independent predictive ability may be related to a degenerative changes in the structure and function of kidneys with increasing age. Baseline eGFR was also a common risk factor for CA-AKI following CAG [28]. eGFR represents worse kidney function and a higher risk of acute kidney injury [29].

Diabetes and contrast volume were not included in our nomogram, although these variables were included in previous models [30]. In our study, diabetes and contrast volume were not independent risk factors for CA-AKI based on statistical analysis. Similar to our finding, Sabeti et al. [31] showed that diabetes mellitus was not an independent risk factor for CA-AKI. A recent review concluded that diabetes
is not independently associated with the risk of developing CA-AKI and only increases susceptibility in patients with underlying kidney disease [32]. Regarding contrast volume, several studies suggested that the development of AKI following contrast exposure is significantly determined by the presence of comorbidities and hemodynamic instability rather than contrast media [33, 34]. Hydration has been considered an effective treatment for CA-AKI, but the actual effect of this strategy is still controversial. Perioperative hydration can expand plasma volume with suppression of the renin-angiotensin-aldosterone system, down-regulation of tubuloglomerular feedback, a decrease of contrast medium concentration in the tubule lumen and vasa recta, and counteraction of medullary vasoconstriction activation[35]. It is still the cornerstone of CIN prevention. But, the rate and duration of hydration remain inconsistent. Meanwhile, the AMACING trial challenged the tenet that intravenous fluids are effective. There was no significant difference in the incidence of CI-AKI between the hydration group and the non-hydration group (2.7% vs 2.6%)[36]. In our study, the volume of hydration was not significantly different in multivariate regression, so this variable was not included in our model. By using our nomogram, clinicians can identify high-risk patients with CA-AKI early and treat them in a timely manner.

Limitations

Our study had some limitations. First, this study was based on data from a single center. However, our cohort is one of the largest CA-AKI databases among patients with hypoalbuminemia.

Second, our model is not as effective as other models, but it has fewer objective variables and higher clinical operability. Importantly, our model has good predictive and evaluative effectiveness in hypoalbuminemia populations.

Third, the nomogram established has not been externally verified. However, we randomly divided all the patients into a development group and a validation group according to a 2:1 ratio, which showed that our model had good stability.

Finally, several patients were discharged 3 days after the operation, so serum creatinine was not measured after 3 days in these patients. This might decrease the development of CA-AKI.

Abbreviations

CA-AKI: contrast-associated acute kidney injury; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CKD: chronic kidney disease; AMI: acute myocardial infarction; DM: diabetes mellitus; CHF: congestive heart failure; LVEF: left ventricular ejection fraction; NYHA: NYHA classification grading of cardiac function; eGFR: estimated glomerular filtration rate; ALB: serum albumin; Lpa: lipoprotein a; BUN: blood urea nitrogen; Dose: dose of contrast media; IABP: intra-aortic balloon pump; Scr: serum creatinine

Declarations
**Ethics approval and consent to participate**

The study was approved by the Ethics Committee of Guangdong Provincial People's Hospital.

**Consent for publication**

Not required.

**Availability of data and materials**

Data relevant to this study are available from the corresponding authors upon reasonable request.

**Competing interests**

All authors declare that they have no competing interests.

**Funding**

This work was supported by the Beijing Lisheng Cardiovascular Pilot Foundation [grant no. LHJJ201612127] and the National Science Foundation of China (grant no. 81670339). The funding body did not participate in the design of the study; the collection, analysis, and interpretation of the data; or in the writing of the manuscript.

**Authors’ contributions**

Substantial contributions to the conception and design of the study (LWL, JL, LL, BW); data collection (GS, ZG, YH, FS, LZ, GC, BL); data analysis and/or interpretation of data for the work (LWL, LL, LY, JYC); drafting of the work or revising it critically for important intellectual content (LWL, LL, JL, LY, JYC); final approval of the version to be published (all the authors).

**Acknowledgements**

None.

**Authors' information**

Jiyan Chen takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the license is given, and an indication of whether changes were made is provided. See https://creativecommons.org/licenses/by/4.0/.
Conflicts of interest: None.

References

1. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380:2146–55.

2. Sun G, Chen P, Wang K, Li H, Chen S, Liu J, et al. Contrast-induced nephropathy and long-term mortality after percutaneous coronary intervention in patients with acute myocardial infarction. Angiology. 2019;70:621–6.

3. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.

4. Brown JR, MacKenzie TA, Maddox TM, Fly J, Tsai TT, Plomondon ME, et al. Acute kidney injury risk prediction in patients undergoing coronary angiography in a national veterans health administration cohort with external validation. J Am Heart Assoc. 2015;4:e002136.

5. González-Pacheco H, Amezcu-Guerra LM, Sandoval J, Martínez-Sánchez C, Ortiz-León XA, Peña-Cabral MA, et al. Prognostic implications of serum albumin levels in patients with acute coronary syndromes. Am J Cardiol. 2017;119:951–8.

6. Justor B, Raquel D, Caroline D, Therese DP, Muteba M, Graham P, et al. Risk factors and outcomes of contrast-induced nephropathy in hospitalised South Africans. S Afr Med J. 2016;106:699–703.

7. Oduncu V, Erkol A, Karabay CY, Kurt M, Akgun T, Bulut M, et al. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis. 2013;24:88–94.

8. Murat SN, Kurtul A, Yarlioglues M. Impact of serum albumin levels on contrast-induced acute kidney injury in patients with acute coronary syndromes treated with percutaneous coronary intervention. Angiology. 2015;66:732–7.

9. Yu MY, Lee SW, Baek SH, Na KY, Chae DW, Chin HJ, et al. Hypoalbuminemia at admission predicts the development of acute kidney injury in hospitalized patients: a retrospective cohort study. PLoS One. 2017;12:e0180750.

10. Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. BMJ. 2015;351:h4395.

11. Liu Y, Chen JY, Tan N, Zhou YL, Yu DQ, Chen ZJ, et al. Safe limits of contrast vary with hydration volume for prevention of contrast-induced nephropathy after coronary angiography among patients with a relatively low risk of contrast-induced nephropathy. Circ Cardiovasc Interv. 2015;8:e001859.

12. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7:1–9.

13. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial
validation. J Am Coll Cardiol. 2004;44:1393–9.

14. Roe MT, Chen AY, Thomas L, Wang TY, Alexander KP, Hammill BG, et al. Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score. Am Heart J. 2011;162:875–83.e1.

15. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J. 2007;153:29–35.

16. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35:1925–31.

17. Lei Z, Li J, Wu D, Xia Y, Wang Q, Si A, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis b virus-related hepatocellular carcinoma within the milan criteria. JAMA Surg. 2016;151:356–63.

18. Nakahashi H, Kosuge M, Sakamaki K, Kiyokuni M, Ebina T, Hibi K, et al. Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention. Heart Vessels. 2017;32:22–9.

19. Kuji S, Kosuge M, Kimura K, Nakao K, Ozaki Y, Ako J, et al. Impact of acute kidney injury on in-hospital outcomes of patients with acute myocardial infarction- results from the japanese registry of acute myocardial infarction diagnosed by universal definition (J-MINUET) substudy. Circ J. 2017;81:733–9.

20. Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol. 2004;57:195–202.

21. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13–9.

22. Ando G, Morabito G, de Gregorio C, Trio O, Saporito F, Oreti G. Age, glomerular filtration rate, ejection fraction, and the AGF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2013;82:878–85.

23. Zeng JF, Chen SQ, Ye JF, Chen Y, Lei L, Liu XQ, et al. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes. Clin Exp Nephrol. 2019;23:969–81.

24. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43:181–93.

25. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780–5.
26. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515–9.

27. Ji L, Su X, Qin W, Mi X, Liu F, Tang X, et al. Novel risk score of contrast-induced nephropathy after percutaneous coronary intervention. Nephrology (Carlton). 2015;20:544–51.

28. McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, et al. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016;68:1465–73.

29. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98:27K–36K.

30. Koo HM, Doh FM, Ko KI, Kim CH, Lee MJ, Oh HJ, et al. Diastolic dysfunction is associated with an increased risk of contrast-induced nephropathy: a retrospective cohort study. BMC Nephrol. 2013;14:146.

31. Sabeti S, Schillinger M, Mlekusch W, Ahmadi R, Minar E. Reduction in renal function after renal arteriography and after renal artery angioplasty. Eur J Vasc Endovasc Surg. 2002;24:156–60.

32. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47:254–61.

33. Wilhelm-Leen E, Montez-Rath ME, Chertow G. Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol. 2017;28:653–9.

34. Hinson JS, Ehmann MR, Fine DM, Fishman EK, Toerper MF, Rothman RE, et al. Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med. 2017;69:577–86.e4.

35. Nagy K, Ujszaszi A, Czira ME, Remport A, Kovesdy CP, Mathe Z, et al. Association between serum resistin level and outcomes in kidney transplant recipients. Transpl Int. 2016;29:352–61.

36. Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389:1312–22.

Figures
Figure 1

Nomogram to estimate the risk of CA-AKI
Figure 2

The receiver operator characteristic curves of the nomogram and the Mehran score in the development cohort.
Figure 3

Validity of the predictive value of the nomogram in the development and validation cohort.
Figure 4

The receiver operator characteristic curves of the nomogram and the Mehran score in the validation cohort.
Figure 5

Association between CA-AKI and long-term mortality in patients with hypoalbuminemia

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TripodChecklist.docx
- Supplementaryfigure1.tiff
- SupplementaryTable.docx